[AMPE] Ampio Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.96 Change: 0.07 (7.91%)
Ext. hours: Change: 0 (0%)

chart AMPE

Refresh chart

Strongest Trends Summary For AMPE

AMPE is in the medium-term down -39% below S&P in 7 months. In the long-term down -85% below S&P in 2 years and down -98% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee and Optina that is in Phase IIb clinical trial for diabetic macular edema. The company, through its subsidiaries, is also involved in the development and commercialization of RedoxSYS, an in-vitro diagnostic platform that measures human oxidation-reduction potential; and Zertane, an oral drug in late stage development as treatment for premature ejaculation in men. Ampio Pha

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.24 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q0% P/E-2.5
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-56.16% ROE-58.34% ROI
Current Ratio19.88 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin-43089.3% Net Profit Margin-41866.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-40 K Cash From Operating Activities-7.01 M Gross Profit
Net Profit-7.28 M Operating Profit-7.6 M Total Assets62.62 M Total Current Assets43.82 M
Total Current Liabilities2.2 M Total Debt Total Liabilities2.34 M Total Revenue20 K
Technical Data
High 52 week3.02 Low 52 week0.39 Last close0.4 Last change0%
RSI50 Average true range0.02 Beta1.36 Volume958.5 K
Simple moving average 20 days-0.99% Simple moving average 50 days-11.31% Simple moving average 200 days-23.35%
Performance Data
Performance Week0% Performance Month-4.76% Performance Quart-25.93% Performance Half-33.09%
Performance Year-34.3% Performance Year-to-date1.32% Volatility daily1.85% Volatility weekly4.14%
Volatility monthly8.49% Volatility yearly29.42% Relative Volume139.12% Average Volume1.2 M
New High New Low

News

2019-09-18 08:30:00 | Ampio Retains Legal Counsel for Transaction Advisory Committee

2019-09-17 08:30:00 | Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

2019-08-22 08:30:00 | Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee

2019-07-25 08:30:00 | Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

2019-07-11 08:30:00 | Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor

2019-07-10 08:30:00 | Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer

2019-06-19 16:01:00 | Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering

2019-06-17 08:16:00 | Ampio Pharmaceuticals Announces Pricing of Public Offering

2019-06-14 16:01:00 | Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

2019-06-14 07:30:00 | Ampio Regulatory and Clinical Update

2019-05-22 08:30:00 | Ampio Clinical, Regulatory and Corporate Update

2019-04-29 08:00:00 | Ampio Pharmaceuticals Provides Regulatory Update

2019-03-26 19:34:00 | Ampio Pharmaceuticals Provides Corporate Update

2019-03-06 08:30:00 | Ampio Updates Regulatory Status for Ampion

2019-02-25 07:40:00 | Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-02-06 08:30:00 | Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA

2018-12-13 06:00:00 | Ampio Updates Regulatory Status for Ampion

2018-11-26 08:30:00 | Ampio Updates Regulatory and Publication status for Ampion™

2018-11-07 16:45:00 | 3 Health Care Stocks Rallying After US Midterms

2018-11-07 08:30:00 | Ampio Updates Regulatory and Clinical Status for Ampion™

2018-10-30 12:23:55 | Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. AMPE and Encourages AMPE Investors to Contact the Firm

2018-10-25 08:55:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth

2018-10-24 15:10:00 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-24 12:00:00 | CLASS ACTION UPDATE for AMPE, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2018-10-23 16:33:40 | Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.

2018-10-23 15:55:23 | SHAREHOLDER ALERT: AMPE LCI PZZA SKX PM USAT COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2018-10-23 11:55:23 | WEDNESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-23 10:00:00 | FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ampio Pharmaceuticals, Inc. AMPE and Lead Plaintiff Deadline – October 24, 2018

2018-10-22 17:10:56 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMPE, OPK, QRTEA and HTHT

2018-10-22 16:25:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm

2018-10-22 13:15:00 | DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-22 11:40:00 | CLASS ACTION UPDATE for AMPE, ALNY and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2018-10-21 22:30:00 | 2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-21 18:00:00 | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Pinduoduo, CV Sciences, and Ampio and Encourages Investors to Contact the Firm

2018-10-21 14:00:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. to Contact The Firm

2018-10-21 11:00:00 | SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2018-10-20 13:50:00 | October 24 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-20 07:00:00 | AMPE OCT. 24 ALERT: Rosen Law Firm Reminds Ampio Pharmaceuticals, Inc. Investors of Important Deadline in First Filed Case Commenced by Firm – AMPE

2018-10-19 18:26:26 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ampio Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – AMPE

2018-10-19 17:05:59 | Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.

2018-10-19 17:00:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm

2018-10-19 14:20:00 | DEADLINE ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-19 13:24:05 | Ampio October 24th Investor Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. - AMPE

2018-10-19 12:01:49 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PDD, AMPE, NVRO, PZZA and TRCO

2018-10-19 10:29:00 | DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ampio Pharmaceuticals, Inc. AMPE and Lead Plaintiff Deadline – October 24, 2018

2018-10-18 15:15:00 | 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2018-10-18 11:31:54 | CLASS ACTION UPDATE for AMPE, NVRO and LOGM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2018-10-17 16:25:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ampio Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - AMPE

2018-10-17 15:07:28 | SHAREHOLDER ALERT: PDD AMPE NVRO LCI CBS PZZA OPK QRTEA PVG COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2018-10-17 13:45:00 | INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm